Efficacy and Safety of TRK-700 in Patient With Post-Herpetic Neuralgia

TRK-700 An Early Phase II Study in Patients With Post-Herpetic Neuralgia -Double Blind Comparison With Placebo-

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02701374

Enrollment

184

Registered

2016-03-08

Start date

2016-03-31

Completion date

2017-07-31

Last updated

2017-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-Herpetic Neuralgia

Keywords

TRK-700, Post-Herpetic Neuralgia

Brief summary

In Post-Herpetic Neuralgia(PHN) patients: * To conduct an explorative investigation of the efficacy and safety of repeated oral doses of TRK-700 via a randomized double blind comparative study * To measure the plasma concentration of TRK-700 and its metabolites

Interventions

DRUGTRK-700

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 84 Years

Healthy volunteers

Inclusion criteria

* Patients with pain persisting for at least 3 months after the onset of herpes zoster * Patients whose average pain score on the Numerical Rating Scale (NRS) over the past 24 hours at preliminary enrollment is at least 4

Exclusion criteria

* Patients with another skin disease that may affect the evaluation of the pain at the site of PHN * Patients with pain other than PHN that may affect the evaluation of pain * Patients with pain that is suspected to be mainly psychogenic * Patients who have received neurolytic or neurosurgical therapy for PHN

Design outcomes

Primary

Measure	Time frame	Description
Change in average Numerical Rating Scale (NRS)	baseline to week 8	Change in average NRS collected by Pain Diary from baseline to week 8 in subjects receiving TRK-700 versus Placebo

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026